Sartorius stock holds near key levels after 2025 results

Sartorius stock stays anchored by 2025 figures, with revenue at EUR 3.38 billion and EBITDA before special items at EUR 929 million. The Sartorius AG group also reported an EBITDA margin of 27.2% for fiscal 2025.

Sartorius stock stays anchored by fiscal 2025 numbers, with Sartorius AG reporting revenue of EUR 3.38 billion and EBITDA before special items of EUR 929 million for the full year 2025. The group also said the EBITDA margin before special items reached 27.2% in 2025, after 26.8% in the prior year.

Margin at 27.2%

The 27.2% margin matters because it came from a full-year 2025 base that still showed a lower top line than the prior year. Sartorius said revenue was down 1.2% at constant currencies in 2025, while EBITDA before special items increased 3.9% year on year to EUR 929 million.

That mix gives the shares a clear reference point: lower sales, but a better margin structure. For investors, the key comparison is the 40-basis-point margin improvement from 26.8% to 27.2% in fiscal 2025.

Revenue and profit mix

The revenue line and the profit line moved in different directions in 2025. Sartorius reported EUR 3.38 billion in sales for the year and EUR 929 million in EBITDA before special items, which means the profit metric outpaced the turnover trend.

The company also said group net profit improved to EUR 156 million in 2025, compared with a loss of EUR 41 million in the prior year. That swing is one of the clearest year-on-year comparisons in the latest report set.

Product line and demand

Sartorius frames its business around laboratory and bioprocess solutions, and the 2025 report kept that segment logic in view. The full-year margin and profit recovery matter more than a product launch on a day when the available evidence is centered on annual reporting.

For the product side, the company’s bioprocess and lab tools portfolio remains the commercial base behind the 2025 revenue figure of EUR 3.38 billion. That link between product demand and margin is what the market can compare against future updates.

Price reference point

The latest evidenced market anchor in the available material is the 2025 report set rather than a fresh intraday quote. Sartorius stock therefore reads mainly through reported operating numbers: EUR 3.38 billion in revenue, EUR 929 million in EBITDA before special items, and EUR 156 million in net profit for 2025.

Those figures give the share a dated, factual base for valuation discussion as of 2025 reporting, with the 27.2% EBITDA margin before special items serving as the cleanest profitability marker.

Sartorius AG

• Company: Sartorius AG
• ISIN: DE0006292006
• Ticker: XETRA: SRT3
• Trading venue: Xetra
• Sector / Industry: Health Care / Life Sciences Tools & Services
• Index membership: MDAX